Editing Hereditary haemochromatosis (section)

===Chelating polymers===
A novel experimental approach to the hereditary haemochromatosis treatment is the maintenance therapy with polymeric chelators.<ref name="Polomoscanik2005">{{cite journal |last1=Polomoscanik |first1=Steven C. |last2=Cannon |first2=C. Pat |last3=Neenan |first3=Thomas X. |last4=Holmes-Farley |first4=S. Randall |last5=Mandeville |first5=W. Harry |last6=Dhal |first6=Pradeep K. |title=Hydroxamic Acid-Containing Hydrogels for Nonabsorbed Iron Chelation Therapy: Synthesis, Characterization, and Biological Evaluation |journal=Biomacromolecules |date=November 2005 |volume=6 |issue=6 |pages=2946–2953 |doi=10.1021/bm050036p |pmid=16283713 }}</ref><ref name="QianSullivan2017">{{cite journal |last1=Qian |first1=Jian |last2=Sullivan |first2=Bradley P. |last3=Peterson |first3=Samuel J. |last4=Berkland |first4=Cory |title=Nonabsorbable Iron Binding Polymers Prevent Dietary Iron Absorption for the Treatment of Iron Overload |journal=ACS Macro Letters |date=18 April 2017 |volume=6 |issue=4 |pages=350–353 |doi=10.1021/acsmacrolett.6b00945 |pmid=35610854 }}</ref><ref name="Groborz2020">{{cite journal |last1=Groborz |first1=Ondřej |last2=Poláková |first2=Lenka |last3=Kolouchová |first3=Kristýna |last4=Švec |first4=Pavel |last5=Loukotová |first5=Lenka |last6=Miriyala |first6=Vijay Madhav |last7=Francová |first7=Pavla |last8=Kučka |first8=Jan |last9=Krijt |first9=Jan |last10=Páral |first10=Petr |last11=Báječný |first11=Martin |last12=Heizer |first12=Tomáš |last13=Pohl |first13=Radek |last14=Dunlop |first14=David |last15=Czernek |first15=Jiří |last16=Šefc |first16=Luděk |last17=Beneš |first17=Jiří |last18=Štěpánek |first18=Petr |last19=Hobza |first19=Pavel |last20=Hrubý |first20=Martin |title=Chelating Polymers for Hereditary Hemochromatosis Treatment |journal=Macromolecular Bioscience |date=December 2020 |volume=20 |issue=12 |page=2000254 |doi=10.1002/mabi.202000254 |pmid=32954629 |s2cid=221827050 }}</ref> These polymers or particles have a negligible or null systemic [[bioavailability|biological availability]] and they are designed to form stable complexes with Fe<sup>2+</sup> and Fe<sup>3+</sup> in the [[gastrointestinal tract|GIT]] and thus limiting the uptake of these ions and their long-term accumulation. Although this method has only a limited efficacy, unlike [[chelation therapy|small-molecular chelators]], such an approach has virtually no [[side effects]] in [[chronic toxicity|sub-chronic studies]].<ref name="Groborz2020" /> Interestingly, the simultaneous chelation of Fe<sup>2+</sup> and Fe<sup>3+</sup> increases the treatment efficacy.<ref name="Groborz2020" />